ARTICLE | Top Story

Exelixis to acquire Genomica

November 19, 2001 8:00 AM UTC

Genomics-based drug discovery company EXEL will acquire GNOM for $110 million in stock. EXEL will use GNOM's bioinformatics software to manage data from future EXEL clinical trials. EXEL said GNOM's cash and short- and long-term investments, which totaled $110.8 million at Sept. 30, will be applied towards its drug discovery programs. ...